A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

The prescription drug has been all over the news in the past couple of years - but the name Ozempic has become something of a ...

A voguish — and often daunting — problem can plague people who have experienced recent and relatively rapid weight loss.

近年来兴起的新型减肥药，例如Ozempic和Wegovy，已经帮助全世界的人们减掉了超过15%的体重，它的作用之夸张，以至于沃尔玛将食品销量的下降归因于这些药物的发明和上市。因此，许多人将这种新一代药物称为社会的“游戏规则改变者”。

Unlike Ozempic, Wegovy is approved for weight management even though they both contain semaglutide. However, they do have ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.

High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...

诺和诺德与Viatris旗下迈兰制药在一份联合文件中表示，已同意解决与诺和诺德减肥药Ozempic和Wegovy相关的专利纠纷。此前诺和诺德已分别在法院起诉Viatris和其他公司侵犯专利，以阻止拟议的仿制药。诺和诺德发言人当地时间10月7日证实了和解协议。 返回搜狐，查看更多 ...

周三，美银证券调整了对诺和诺德公司（NYSE:NVO）股票的展望，将目标价从之前的166.00美元下调至159.50美元，同时维持对该股票的买入评级。这一调整是因为分析师预计第三季度集团销售额将达到约694亿丹麦克朗，同比增长18%，息税前利润（EBIT）将达到约330亿丹麦克朗，较上年同期增长23%。尽管有这些增长，预测的EBIT比共识预期低约4%。

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...